Flavia Matovu Kiweewa

Datos Biográficos

ID	7726539
NOMBRE	Flavia Matovu Kiweewa
NOMBRES	Flavia Matovu
APELLIDO	Kiweewa
FIRMA	KIWEEWA F M
AFILIACIONES	MUJHU Research Collaboration
ORCID	0000-0002-0046-4353
VERIFICADO	Sí
TOTAL DE OBRAS	12
TOTAL DE CITAS	0
TOTAL COMO AUTOR	12
TOTAL COMO EDITOR	0
PRIMER AÑO DE PUBLICACIÓN	2015
AÑO MÁS RECIENTE DE PUBLICACIÓN	2024
ÍNDICE H	0

Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence
Open AccessMarla Husnik, Renee Heffron et al.ARTICLEAIDS and Behavior2024
Depression and PrEP uptake, interruption, and adherence among young women in Uganda
Open AccessYasaman Zia, Lydia Nambala et al.ARTICLEAIDS Care2023
Depression is a common cause of morbidity globally and can impact adherence to medications, posing challenges to medication-based HIV prevention. The objectives of this work are to describe the frequency of depression symptoms in a cohort of 499 young women in Kampala, Uganda and to determine the association of depression symptoms with use of HIV pre-exposure prophylaxis (PrEP). Mild or greater depression, assessed by the patient health questionn…
Factors associated with willingness to use oral pre-exposure prophylaxis (PrEP) in a fisher-folk community in peri-urban Kampala, Uganda
Open AccessBashir Ssuna, Anne Katahoire et al.ARTICLEBMC Public Health2022
Oral PrEP was widely acceptable among members of fishing communities in peri-urban Kampala. Programs for scaling-up PrEP for fisherfolk should merge HIV testing services with sensitization about PrEP and also increase means of awareness of PrEP as an HIV preventive strategy
Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/Aspire study
Open AccessMorgan Garcia, Ellen Luecke et al.ARTICLEBMC Public Health2021
Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be consi…
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
Open AccessMarla Husnik, Elizabeth R Brown et al.ARTICLEAIDS and Behavior2021
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
Open AccessAshley Mayo, Erica N Browne et al.ARTICLEAIDS and Behavior2021
We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15-30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonad…
The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence
Open AccessMarie C D Stoner, Elizabeth R Brown et al.ARTICLEAIDS and Behavior2021
Perceived risk versus objectively measured risk of HIV acquisition
Open AccessLillian Tugume, Timothy R Muwonge et al.ARTICLEBMC Public Health2019
Incongruence between perceived and objectively measured risk of HIV acquisition does occur especially among individuals whose partners had a detectable viral load. PrEP counselling for serodiscordant couples should focus on explaining the consequence of detectable viral load in the HIV-positive partner on HIV transmission risk
Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial
Open Accessfor the MTN-020/ASPIRE Team, Sarah T Roberts et al.ARTICLEAIDS and Behavior2019
Vaginal Ring Use in a Phase 3 Microbicide Trial
Open AccessBarbara S Mensch, Barbra A Richardson et al.ARTICLEAIDS and Behavior2018
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Jared M Baeten, Thesla Palanee‐phillip et al.ARTICLENew England Journal of Medicine2016
BACKGROUND: Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence. Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection. METHODS: We conducted a ph…
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, “the Nevirapine Repeat Pregnancy study”
Open AccessFlavia Matovu Kiweewa, Paul M Bakaki et al.ARTICLEBMC Public Health2015
Results from this study show high overall HIV disclosure proportions and how this disclosure of HIV status can foster social support. However, proportions of disclosure specifically to male sex partners were low, which suggests the need for interventions aimed at increasing male involvement in perinatal care, along with supportive counseling